Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2006-03-14
2010-06-08
Chen, Stacy B (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S192100, C424S204100, C424S209100
Reexamination Certificate
active
07732130
ABSTRACT:
The present invention relates to an influenza antigen, comprising a fusion product of at least the extracellular part of a conserved influenza membrane protein or a functional fragment thereof and a presenting carrier, which may be a presenting (poly)peptide or a non-peptidic structure, such as glycans, peptide mimetics, synthetic polymers. The invention further relates to a vaccine against influenza, comprising at least an antigen of the invention, optionally in the presence of one or more excipients. The invention also relates to use of the antigen, a method for preparing the antigen and acceptor cells expressing the antigen.
REFERENCES:
patent: 3919044 (1975-11-01), Melnick et al.
patent: 5691189 (1997-11-01), Kurtz et al.
patent: 5843446 (1998-12-01), Ladd et al.
patent: 5871747 (1999-02-01), Gengoux-Sedlik et al.
patent: 6169175 (2001-01-01), Frace et al.
patent: 49273 90 (1990-08-01), None
patent: A-49273/90 (1990-08-01), None
patent: WO 92/22575 (1992-12-01), None
patent: WO 94/06472 (1994-03-01), None
patent: WO 98/23735 (1998-06-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 01/49886 (2001-07-01), None
patent: WO 01/49886 (2001-07-01), None
patent: WO 01/59886 (2001-07-01), None
Gerhard et al. Emerging Infectious Diseases, Apr. 2006, 12(4):569-574.
Neirynck et al. Nature Medicine, Oct. 1999, 5(10):1157-1163.
Armerding, et al., “Evaluation of live and inactivated influenza A virus vaccines in a mouse model”J Infect Dis145(3):320-30 (1982).
Arnon, et al., “Synthetic recombinant vaccines against viral agents”Int Arch Allergy Immunol108(4):321-6 (1995).
Asanuma, et al., “Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration”Vaccine13(1):3-5 (1995).
Bachmayer, et al., “Potency of influenza vaccines: mouse protection experiments in correlation to field studies in man”Dev. Biol Stand28:336-9 (1975).
Baez, et al., “Gene composition of high-yielding influenza vaccine strains obtained by recombination”J Infect Dis141:362-365 (1980).
Bastin, et al., “Use of synthetic peptides of influenza nucleoprotein to define epitopes recognized by class I-restricted cytotoxic T lymphocytes”J Exp. Med.165:1508-1523 (1987).
Bednarek, et al., “The minimum peptide epitope from the influenza-virus matrix protein. Extra and intracellular loading of HLA-A2”J Immunol147:4047-4053 (1991).
Ben-Ahmeida, et al., “IgG subclass response and protection against challenge following immunisation of mice with various influenza A vaccines”J Med Microbiol40(4):261-9 (1994).
Berendt, et al., “Evaluation of commercially prepared vaccines for experimentally induced type A/New Jersey/8/76 influenza virus infections in mice and squirrel monkeys”J. Infect Dis136 Suppl:S712-7 (1977).
Betakova, et al., “The NB protein is an integral component of the membrane of influenza B virus”J Gen Virol77(Pt 11):2689-94 (1996).
Bodmer, et al., “Enhanced Recognition of a Modified Peptide Antigen by Cytotoxic T Cells Specific for Influenza Nucleoprotein”Cell52:253-258 (1988).
Bottex, et al., “Comparative immunogenicity of live influenza viruses and their solubilized neuraminidases: results of mouse protection experiments”Arch Virol70(2):83-9 (1981).
Brassard, et al., “Influenza B virus NB glycoprotein is a component of the virion”Virology220(2):350-60 (1996).
Brett, et al., “Human T Cell Recognition of Influenza A Nucleoprotein. Specificity and Genetic Restriction of Immunodominant T Helper Cell Epitopes”J Immunol147:984-991 (1991).
Ceppelini, et al., “Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells”Nature339, 392-394 (1989).
Cerundolo, et al., CD8 independence and specificity of cytotoxic T-lymphocytes restricted by HLAAw68.1. Proc Roy Soc Lond Series B boil Sci244:169-177 (1991).
Chen, et al., “Protection against influenza B virus infection by immunization with DNA vaccines”Vaccine19:1446-1455 (2001).
Cruse, et al.,Illustrated Dictionary of Immunology, pp. 46 and 229 (1995).
Deck, et al., “Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine”Vaccine15(1):71-8 (1997).
de Haan, et al., “Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes”Vaccine13(2):155-62 (1995).
Deroo, et al., “Recombinant neuraminidase vaccine protects against lethal influenza”Vaccine14(6):561-9 (1996).
de Velasco, et al., “Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines”Infect Immun63(3):961-8 (1995).
DiBrino, et al., “HLA-A1 and HLA-A3 T-cell epitopes derived from influenza-virus proteins predicted from peptide bindingmotifs”J Immunol151:5930-5935 (1993).
Dong, et al., “An HLA-B35-restricted epitope modified at an anchor residue results in an antagonist peptide”Eur J Immunol26:335-339 (1996).
Dorland's Illustrated Dictionary, 1994, 28th ed., Philadelphia; WB Sauders Company, p. 1254.
Estabrook, et al., “Monoclonal antibodies: their importance to surgeons”J. Invest. Surg.2(3): 211-22 (1989) abstract only.
Fan, et al., “Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys”Vaccine22:2993-3003 (2004).
Fields, et al.,Virology3rd ed., 1996, Philadelphia; Lippencott, Williams, and Wilkins, pp. 1400 and 1417.
Fields,Virology4th ed., p. 1541 (2001).
Friede, et al., “Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered inliposomes”Vaccine12(9):791-7 (1994).
Gao, et al., “Identification and Characterization of T Helper Epitopes in the Nucleoprotein of Influenza A virus”J Immunol143:3007-3014 (1989).
Gao, “Priming of influenza virus-specific cytotoxic T lymphocytes vivo by short synthetic peptides”J Immunol147:3268-3273 (1991).
Ghazi, et al., “Comparative antibody responses and protection in mice immunised by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMs”J Med Microbiol42(1):53-61 (1995).
Ghazi, et al., “Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice”Arch Virol140(6):1015-31 (1995).
Gotch, et al., “Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2”Nature326:881-882 (1987).
Govorkova, et al., “Cross-protection of mice immunized with different influenza A (H2) strains and challenged with viruses of the same HA subtype”Acta Virol41(5):251-7 (1997).
Gray, et al., “pH-induced conformational changes of membrane-bound influenza hemagglutinin and its effect on target lipid bilayers”Protein Science7(11):2359-73 (1998) abstract only.
Hay, “Functional Properties of the Virus Ion Channels”Textbook of Influenza7:74-81 (1998).
Heinen, et al., “Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus”J of Gen. Virol83:1851-1859 (2002).
Hirabayashi, et al., “Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination”Vaccine8(3):243-8 (1990).
Hjorth, et al., “The effect of syntex adjuvant formulation (SAF-m) on humoral immunity to the influenza virus in the mouse”Vaccine15(5):541-6 (1997).
Hongo, et al., “Identification of a second protein encoded by influenza C virus RNA segment 6”J Gen Virol75(Pt12):3503-10 (1994).
Hongo, et al., “Characterization of a second protein (CM2) encoded by RNA seg
Fiers Walter
Jou Willy Min
Neirynck Sabine
Chen Stacy B
Husch Blackwell Sanders Welsh & Katz
Vlaams Interuniversitair Instituut Voor Biotechnolgoie
LandOfFree
Immunoprotective influenza antigen and its use in vaccination does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunoprotective influenza antigen and its use in vaccination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoprotective influenza antigen and its use in vaccination will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4230017